UroGen Pharma Ltd (URGN NASDAQ) stock market data APIs
$24.1791
0.19(0.8%)
as of April 24, 2026
Try our APIs with
free plan!
UroGen Pharma Ltd Financial Data Overview
Price chart is built with
Anychart
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Prev. Close
24.1791
Open
24.3705
High
24.8233
Low
23.8553
52 wk Range
3.42-30
Market Cap
1 183 M
Shares Outstanding
48 682 K
Revenue
110 M
EPS
-0.53
Beta
1.439
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with UroGen Pharma Ltd (top by weight)
Ticker
100-day Price Change
Weight
ISRCF.US
iShares V Public Limited Company - iShares S&P 500 Information Technology Sector UCITS ETF
3.8
(9.18%)
0.18
ISRWF.US
iShares II Public Limited Company - iShares J.P. Morgan $ Emerging Markets Bond UCITS ETF
1.92
(2.1%)
0.17
ISRVF.US
iShares Public Limited Company - iShares MSCI Japan USD Hedged UCITS ETF (Acc)
3.85
(3.64%)
0.17
ISRNF.US
iShares V Public Limited Company - iShares S&P 500 Consumer Discretionary Sector UCITS ETF
-1.52
(-8.63%)
0.17
ISRIF.US
iShares IV Public Limited Company - iShares $ Treasury Bond 20+yr UCITS ETF
0.01
(0.28%)
0.17
ISRZF.US
iShares II Public Limited Company - iShares $ High Yield Corporate Bond UCITS ETF
0.28
(0.29%)
0.17
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get UroGen Pharma Ltd data using free add-ons & libraries
Get UroGen Pharma Ltd Fundamental Data
UroGen Pharma Ltd Fundamental data includes:
- Net Revenue: 110 M
- EBITDA: -124 556 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-02
- EPS/Forecast: -0.4821
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
UroGen Pharma Ltd News
New
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened ...
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain
On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics(NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter. What happened Ac...
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet?
Superstring Capital Management initiated a new position in Sionna Therapeutics(NASDAQ:SION), acquiring 180,593 shares in the fourth quarter. What happened According to a February 17, 2026, SEC filin...
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
On February 17, 2026, Superstring Capital Management disclosed a new position in Definium Therapeutics(NASDAQ:DFTX), acquiring 425,202 shares in the fourth quarter. What happened According to a SEC ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
